-
NIH, MSKCC researchers publish AI model for predicting immunotherapy responses
Researchers at Memorial Sloan Kettering Cancer Center and the National Institutes of Health’s National Cancer Institute said their AI approach was able to identify patients more likely to have objective responses to immune checkpoint inhibitors as well as forecast short- and long-term survival among different cancers. (Getty Images)
-
ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
A new trend has emerged at this year’s American Society of Clinical Oncology conference: the possibility of replacing decades-old chemotherapy with novel approaches. “We want to be part of that wave,” AbbVie Pedro Valencia, Ph.D., AbbVie’s vice president of solid tumor pipeline strategy and execution, told Fierce Biotech onsite in Chicago. “This is the ASCO…
-
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
KEY POINTS Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results. Their prospects through 2030 look excellent thanks to some major products.
June 2024
Archive
Categorise
Recent Posts
- Citing ‘capacity constraints,’ Novo Nordisk plots global wind-down of human insulin pen production
- NIH, MSKCC researchers publish AI model for predicting immunotherapy responses
- ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
- Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
- 8 Biotech Companies in Chicago Cultivating the City’s Life Sciences Scene
